BNBX
BNB Plus Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.16
+0.00%Year over year
Reported trailing growth
- Revenue
- -39.6%
- EBITDA
- —
- EBIT
- -94.7%
- EPS
- —
- Free cash flow
- +1.1%
- Operating cash flow
- -4.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -51.0%
- EBITDA
- —
- EBIT
- -14.4%
- Net income
- —
- EPS
- -96.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026